-
公开(公告)号:WO2022099066A1
公开(公告)日:2022-05-12
申请号:PCT/US2021/058326
申请日:2021-11-05
发明人: MCGOWAN, David Craig , RABOISSON, Pierre Jean-Marie Bernard , VANDYCK, Koen , DEVAL, Jerome , BEIGELMAN, Leonid
IPC分类号: C07D209/96 , C07D403/12 , C07D413/12 , C07D471/04 , A61P3/00 , A61K31/53
摘要: Disclosed herein are compounds of Formula I': or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a subject with one or more of the above compounds.
-
公开(公告)号:WO2022087021A1
公开(公告)日:2022-04-28
申请号:PCT/US2021/055686
申请日:2021-10-19
申请人: FZATA, INC.
发明人: YANG, Zhiyong , YU, Hua
IPC分类号: G01N33/569
摘要: Described herein, are methods of detecting neutralizing antibodies that bind to Clostridioides difficile (C. diff) toxin B (TcdB), prognosing the disease severity of Clostridioides difficile infection (CDI) and the risk of primary and recurrent CDI, as well as providing a guide for clinical practice. Also described herein are kits for performing the methods of this disclosure.
-
公开(公告)号:WO2019164594A3
公开(公告)日:2019-08-29
申请号:PCT/US2019/012701
申请日:2019-01-08
申请人: EPICENTRX, INC.
发明人: ORONSKY, Bryan T. , ORONSKY, Arnold
IPC分类号: A61K31/397 , A61K45/06 , A61P35/00 , A61P39/00
摘要: Provided herein are therapeutic methods, kits, and pharmaceutical compositions for protecting a subject from radiation using a therapeutic agent selected from the group consisting of RRx-001 and a pharmaceutically acceptable salt thereof. One exemplary therapeutic method involves administering RRx-001 to the subject prior to the subject being exposed to the radiation, in order to protect the subject against radiation, such as ionizing radiation containing α-rays, β- rays, γ-rays, neutron radiation, or a combination thereof.
-
公开(公告)号:WO2019164593A3
公开(公告)日:2019-08-29
申请号:PCT/US2019/012696
申请日:2019-01-08
申请人: EPICENTRX, INC.
IPC分类号: A61K31/397 , A61K31/661 , A61K45/06 , A61P35/00 , A61P39/00
摘要: Provided herein are therapeutic methods, kits, and pharmaceutical compositions for protecting a subject from radiation using a therapeutic agent selected from the group consisting of RRx-OOl and a pharmaceutically acceptable salt thereof. One exemplary therapeutic method involves administering RRx-OOl to the subject prior to the subject being exposed to the radiation, in order to protect the subject against radiation, such as ionizing radiation containing α-rays, β- rays, γ-rays, neutron radiation, or a combination thereof.
-
公开(公告)号:WO2018132400A1
公开(公告)日:2018-07-19
申请号:PCT/US2018/013055
申请日:2018-01-10
发明人: ROWLAND, Charles , OWEN, Renius , STROM, Charles , ZHANG, Ke
摘要: The present disclosure provides methods for non-invasive prenatal screening (NIPS) of fetal aneuploidies. The present methods are based on analyzing cell-free fetal DNA (cff DNA) found in a pregnant woman's circulation through the next generation sequencing (NGS) technology. Particularly, the present methods analyze the relative abundance of different fetal genomic fragments present in the maternal sample, where the fragments can be aligned to particular chromosomal locations of the fetal genome. The relative abundance information is indicative as to whether a particular chromosome is overrepresented or underrepresented in a fetal genome as compared to normal individuals, and thus can be used to detect fetal aneuploidy. Additionally, methods for increasing the positive predictive values (PPV) of NIPS by excluding false-positive detections are also provided.
-
公开(公告)号:WO2018093723A1
公开(公告)日:2018-05-24
申请号:PCT/US2017/061311
申请日:2017-11-13
发明人: SANDERS, Heather , CLARKE, Nigel J.
IPC分类号: C12Q1/68
摘要: The present disclosure provides methods for determining whether a patient exhibiting cystic fibrosis symptoms, or a patient at risk for cystic fibrosis, will benefit from treatment with one or more anti-cystic fibrosis therapeutic agents. These methods are based on detecting hereditary cystic fibrosis related mutations in small-volume dried biological fluid samples that are collected using a volumetric absorptive microsampling device. Kits for use in practicing the methods are also provided.
-
公开(公告)号:WO2018071504A3
公开(公告)日:2018-04-19
申请号:PCT/US2017/056082
申请日:2017-10-11
发明人: BAUM, Patrick , BOECHER, Wulf Otto , GALLER, Annette Bettina , LALOVIC, Bojan , VISVANATHAN, Sudha
IPC分类号: C07K16/24 , A61K39/395 , A61P29/00
摘要: This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as Crohn's Disease, utilizing anti-IL-23A antibodies.
摘要翻译: 本发明一般涉及利用抗IL-23A抗体治疗IL-23相关疾病,特别是炎性疾病如克罗恩氏病的方法。 P>
-
公开(公告)号:WO2018071504A2
公开(公告)日:2018-04-19
申请号:PCT/US2017/056082
申请日:2017-10-11
发明人: BAUM, Patrick , BOECHER, Wulf Otto , GALLER, Annette Bettina , LALOVIC, Bojan , VISVANATHAN, Sudha
IPC分类号: C07K16/24 , A61K39/395 , A61P29/00
摘要: This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as Crohn's Disease, utilizing anti-IL-23A antibodies.
摘要翻译: 本发明一般涉及利用抗IL-23A抗体治疗IL-23相关疾病,特别是炎性疾病如克罗恩氏病的方法。 P>
-
公开(公告)号:WO2018035303A1
公开(公告)日:2018-02-22
申请号:PCT/US2017/047308
申请日:2017-08-17
发明人: WAGNER, Thomas E.
摘要: The disclosed bead vectors direct entry into a cell of monocytic origin and cause the expression of an extracellular domain of PD-1, an anti-CTLA4 antibody, or an antibody that is specific for a checkpoint protein. The bead vectors can comprise a nucleic acid component, a lysosome evading component and a bead particle that can be phagocytized. The disclosed vectors are useful in various methods of cancer therapy, treatment, and prevention. Due to the ability of monocytic cells to target tumors, the disclosed vectors are particularly well suited for use in anti-tumor applications and directing expression of target genes in tumor-associated macrophages.
摘要翻译: 所公开的珠载体直接进入单核细胞来源的细胞并引起PD-1的胞外域,抗-CTLA4抗体或对检查点蛋白特异性的抗体的表达。 珠载体可包含核酸组分,溶酶体逃避组分和可被吞噬的珠粒。 所公开的载体可用于癌症治疗,治疗和预防的各种方法中。 由于单核细胞靶向肿瘤的能力,所公开的载体特别适合用于抗肿瘤应用和指导靶基因在肿瘤相关巨噬细胞中的表达。 p>
-
公开(公告)号:WO2017165599A1
公开(公告)日:2017-09-28
申请号:PCT/US2017/023735
申请日:2017-03-23
发明人: CHEN, Jules , TABB, Michelle
摘要: The present disclosure provides methods for determining whether a patient exhibiting pertussis-like symptoms will benefit from treatment, with therapeutic agents that inhibit Bordetella holmesii . These methods are based on detecting Bordetella pertussis , Bordetella parapertussis , and Bordetella holmesii in a biological sample by assaying for the presence of the IS481, IS 1001, and hIS1001 target repeat elements, respectively. Kits for use in practicing the methods are also provided.
摘要翻译: 本公开提供了用治疗药物来确定展示百日咳样症状的患者是否将从治疗中获益的方法,所述治疗药物抑制博德特氏菌博德特氏菌(Bordetella holmesii)。 这些方法基于通过测定生物样品中的百日咳博德特氏菌,副百日咳博德特氏菌和博德特氏菌霍尔姆氏菌的检测 IS481,IS 1001和hIS1001目标重复元素的存在。 还提供了用于练习这些方法的试剂盒。 p>
-
-
-
-
-
-
-
-
-